» Articles » PMID: 20370804

Acetylcholine-dopamine Interactions in the Pathophysiology and Treatment of CNS Disorders

Overview
Specialties Neurology
Pharmacology
Date 2010 Apr 8
PMID 20370804
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Dopaminergic neurons in the substantia nigra pars compacta and ventral tegmental area of the midbrain form the nigrostriatal and mesocorticolimbic dopaminergic pathways that, respectively, project to dorsal and ventral striatum (including prefrontal cortex). These midbrain dopaminergic nuclei and their respective forebrain and cortical target areas are well established as serving a critical role in mediating voluntary motor control, as evidenced in Parkinson's disease, and incentive-motivated behaviors and cognitive functions, as exhibited in drug addiction and schizophrenia, respectively. Although it cannot be disputed that excitatory and inhibitory amino acid-based neurotransmitters, such as glutamate and GABA, play a vital role in modulating activity of midbrain dopaminergic neurons, recent evidence suggests that acetylcholine may be as important in regulating dopaminergic transmission. Midbrain dopaminergic cell tonic and phasic activity is closely dependent upon projections from hindbrain pedunculopontine and the laterodorsal tegmental nuclei, which comprises the only known cholinergic inputs to these neurons. In close coordination with glutamatergic and GABAergic activity, these excitatory cholinergic projections activate nicotinic and muscarinic acetylcholine receptors within the substantia nigra and ventral tegmental area to modulate dopamine transmission in the dorsal/ventral striatum and prefrontal cortex. Additionally, acetylcholine-containing interneurons in the striatum also constitute an important neural substrate to provide further cholinergic modulation of forebrain striatal dopaminergic transmission. In this review, we examine neurological and psychopathological conditions associated with dysfunctions in the interaction of acetylcholine and dopamine and conventional and new pharmacological approaches to treat these disorders.

Citing Articles

Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.

Solmi M, Fornaro M, Caiolo S, Lussignoli M, Caiazza C, De Prisco M Mol Psychiatry. 2024; 30(3):1207-1222.

PMID: 39695322 DOI: 10.1038/s41380-024-02733-z.


Striatal Cholinergic Interneurons Control Physical Nicotine Withdrawal via Muscarinic Receptor Signaling.

Kim B, Kim H, Woo J, Lee H, Kim T, Min H Adv Sci (Weinh). 2024; 11(47):e2402274.

PMID: 39491887 PMC: 11653618. DOI: 10.1002/advs.202402274.


Studies and Antioxidant and Neuroprotective Assessment of Microencapsulated Celecoxib against Scopolamine-induced Alzheimer's Disease.

Vishnumurthy R, Priya M, Tiwari P, Solomon V Curr Pharm Des. 2024; 31(4):320-329.

PMID: 39206485 DOI: 10.2174/0113816128298289240723103828.


Emotional vocalizations alter behaviors and neurochemical release into the amygdala.

Ghasemahmad Z, Mrvelj A, Panditi R, Sharma B, Perumal K, Wenstrup J Elife. 2024; 12.

PMID: 39008352 PMC: 11249735. DOI: 10.7554/eLife.88838.


Drug Development for Alzheimer's and Parkinson's Disease: Where Do We Go Now?.

Sequeira L, Benfeito S, Fernandes C, Lima I, Peixoto J, Alves C Pharmaceutics. 2024; 16(6).

PMID: 38931832 PMC: 11206728. DOI: 10.3390/pharmaceutics16060708.


References
1.
Zweig R, Jankel W, Hedreen J, Mayeux R, Price D . The pedunculopontine nucleus in Parkinson's disease. Ann Neurol. 1989; 26(1):41-6. DOI: 10.1002/ana.410260106. View

2.
Yeomans J . Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 1995; 12(1):3-16. DOI: 10.1038/sj.npp.1380235. View

3.
Stone J, Pilowsky L . Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets. 2007; 6(4):265-72. DOI: 10.2174/187152707781387323. View

4.
Gerfen C, Engber T, Mahan L, Susel Z, Chase T, Monsma Jr F . D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990; 250(4986):1429-32. DOI: 10.1126/science.2147780. View

5.
Caulfield M, Birdsall N . International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998; 50(2):279-90. View